141 related articles for article (PubMed ID: 11032938)
1. Evaluation of inflammatory cytokines in malignant and benign pleural effusions.
Alexandrakis MG; Coulocheri SA; Bouros D; Mandalaki K; Karkavitsas N; Eliopoulos GD
Oncol Rep; 2000; 7(6):1327-32. PubMed ID: 11032938
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion.
Chung CL; Chen YC; Chang SC
Chest; 2003 Apr; 123(4):1188-95. PubMed ID: 12684310
[TBL] [Abstract][Full Text] [Related]
3. Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
Chung CL; Chen CH; Sheu JR; Chen YC; Chang SC
Chest; 2005 Aug; 128(2):690-7. PubMed ID: 16100155
[TBL] [Abstract][Full Text] [Related]
4. Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
Hua CC; Chang LC; Chen YC; Chang SC
Chest; 1999 Nov; 116(5):1292-6. PubMed ID: 10559090
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ferritin, interleukin-6, interleukin-8 and tumor necrosis factor alpha in the differentiation of exudates and transudates in pleural effusions.
Alexandrakis MG; Coulocheri SA; Bouros D; Eliopoulos GD
Anticancer Res; 1999; 19(4C):3607-12. PubMed ID: 10629659
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid levels are increased in complicated parapneumonic pleural effusions.
Zaga T; Makris D; Tsilioni I; Kiropoulos T; Oikonomidi S; Damianos A; Gourgoulianis KI
Monaldi Arch Chest Dis; 2011 Sep; 75(3):167-71. PubMed ID: 22428219
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
8. Role of monocyte chemoattractant protein-1, tumor necrosis factor-alpha and interleukin-6 in the control of malignant pleural effusion and survival in patients with primary lung adenocarcinoma.
Qian Q; Sun WK; Zhan P; Zhang Y; Song Y; Yu LK
Int J Biol Markers; 2012 Jul; 27(2):e118-24. PubMed ID: 22505233
[TBL] [Abstract][Full Text] [Related]
9. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
[TBL] [Abstract][Full Text] [Related]
10. Cytokines and fibrinolytic enzymes in tuberculous and parapneumonic effusions.
Lin FC; Chen YC; Chen FJ; Chang SC
Clin Immunol; 2005 Aug; 116(2):166-73. PubMed ID: 15897010
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of etoposide after intrathoracic instillation to lung cancer patients with pleural effusion.
Wada I; Yokouchi M; Saitoh H; Takada M; Nakabayashi T; Mino K; Honma T; Takeda T; Hirano K
Int J Clin Pharmacol Ther; 1999 May; 37(5):254-9. PubMed ID: 10363625
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions.
Xirouchaki N; Tzanakis N; Bouros D; Kyriakou D; Karkavitsas N; Alexandrakis M; Siafakas NM
Chest; 2002 Mar; 121(3):815-20. PubMed ID: 11888965
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions.
Hamed EA; El-Noweihi AM; Mohamed AZ; Mahmoud A
Respirology; 2004 Mar; 9(1):81-6. PubMed ID: 14982607
[TBL] [Abstract][Full Text] [Related]
14. Cell origins and diagnostic accuracy of interleukin 27 in pleural effusions.
Yang WB; Liang QL; Ye ZJ; Niu CM; Ma WL; Xiong XZ; Du RH; Zhou Q; Zhang JC; Shi HZ
PLoS One; 2012; 7(7):e40450. PubMed ID: 22792330
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines.
Mantovani G; Macciò A; Pisano M; Versace R; Lai P; Esu S; Massa E; Ghiani M; Dessì D; Melis GB; Del Giacco GS
Int J Cancer; 1997 May; 71(5):724-31. PubMed ID: 9180137
[TBL] [Abstract][Full Text] [Related]
16. Acute phase markers for the differentiation of infectious and malignant pleural effusions.
Kiropoulos TS; Kostikas K; Oikonomidi S; Tsilioni I; Nikoulis D; Germenis A; Gourgoulianis KI
Respir Med; 2007 May; 101(5):910-8. PubMed ID: 17270413
[TBL] [Abstract][Full Text] [Related]
17. Mechanism for the recruitment of macrophages to cancer site. In vivo concentration gradient of monocyte chemotactic activity.
Martinet N; Beck G; Bernard V; Plenat F; Vaillant P; Schooneman F; Vignaud JM; Martinet Y
Cancer; 1992 Aug; 70(4):854-60. PubMed ID: 1379511
[TBL] [Abstract][Full Text] [Related]
18. Interleukin -1beta (IL-1 beta), interleukin 6 (IL-6) and tumor necrosis factor (TNF) in plasma and pleural fluid of pneumonia, lung cancer and tuberculous pleuritis.
Ilonidis G; Parapanisiou E; Anogeianaki A; Giavazis I; Theofilogiannakos EK; Tsekoura P; Kidonopoulou K; Trakatelli C; Polimenidis Z; Conti P; Anogianakis G
J Biol Regul Homeost Agents; 2006; 20(1-2):41-6. PubMed ID: 18088554
[TBL] [Abstract][Full Text] [Related]
19. IL-8 in pleural effusion.
Ceyhan BB; Ozgün S; Celikel T; Yalçin M; Koç M
Respir Med; 1996 Apr; 90(4):215-21. PubMed ID: 8736655
[TBL] [Abstract][Full Text] [Related]
20. The comparison of pleural fluid TNF-α levels in tuberculous and nontuberculous pleural effusion.
Damayanti N; Yudhawati R
Indian J Tuberc; 2020 Jan; 67(1):98-104. PubMed ID: 32192626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
